Quick Answer
Maze Therapeutics, Inc. reported Stockholders Equity of $354.97 million for fiscal year 2025.
Maze Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $354.97M | +214.1% |
| 2024 | -$311.18M | +16.8% |
| 2023 | -$373.85M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $379.44M | +233.4% | +44.7% |
| June 30, 2025 | $262.24M | +199.9% | -10.2% |
| March 31, 2025 | $292.07M | +172.4% | +193.9% |
| December 31, 2024 | -$311.18M | +16.8% | -9.4% |
| September 30, 2024 | -$284.53M | — | -8.4% |
| June 30, 2024 | -$262.37M | — | +35.0% |
| March 31, 2024 | -$403.66M | — | -8.0% |
| December 31, 2023 | -$373.85M | — | — |
- Maze Therapeutics, Inc. showed an increase of +214.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Maze Therapeutics, Inc.’s stockholders equity has grown by 194.9% (from -$373.85 million to $354.97 million).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: